Blood tests measuring circulating gluten-specific CD4+ T cells or measuring IL-2 in the serum after bolus gluten challenge could confirm CeD diagnosis and possibly also stratify disease severity based on the “strength” of the immune response to gluten in vivo [32,75,76]. Here, IL2 is linked to cranioectodermal dysplasia.